According to a press release from Syndax Pharmaceuticals, the developer of Revumenib, the drug met its primary endpoint resulting in complete remission (CR) or CR with partial recovery. Relapsed or…
Researchers have unveiled a groundbreaking laboratory model that could transform the search for new therapies against an aggressive and often lethal blood cancer: acute myeloid leukemia (AML). AML is notorious…
A study conducted by researchers from the Institute of Cancer Research in London and Cyclacel has recently been published in PLOS ONE. This investigation examined fadraciclib as a potential therapy…
According to a publication from MarketScreener, pharmaceutical titan Pfizer Inc. has gained FDA approval for Daurismo, a once-a-day oral medication designed to be paired with low-dose cytarabine (a type of…
The Scottish Medicines Consortium, a committee that advises NHS Scotland on what medicines they should provide, has accepted four new drugs for use. These are gemtuzumab ozogamicin for acute myeloid…
The company Imago Biosciences, which focuses on developing anti-cancer therapies, is carrying out a Phase 1/2a clinical study of an investigational drug called IMG-7289 as a potential treatment for…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
